Marken President Ariette Van Strien addresses whether the momentum toward decentralized trials will continue after the pandemic: “As an industry, each and every one of us plays a part in ensuring that decentralized trials continue to take hold and find increasing traction and success,” she says. “The question of whether or not the momentum can be maintained post-COVID-19 simply isn’t a question or an option. It’s an imperative.”